Christopher Richard Anzalone sold $12M of ARWR
Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC.. 184,298 shares at an average of $67.00, traded Dec 15, 2025, filed Dec 16, 2025.
Score components
- +25RoleCEO
- +25Trade size$12.3M at market
- 0Share of holdings soldSold 4.5% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001423029-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2025 | AGrant or award Common Stock | +180,000 | $0.00 | $0 | 4,101,255 | Dec 16, 2025 |
| Dec 15, 2025 | SOpen-market sale Common Stock | -100,532 | $68.67 | $6.9M | 4,000,723 | Dec 16, 2025 |
| Dec 15, 2025 | SOpen-market sale Common Stock | -21,321 | $69.28 | $1.5M | 3,979,402 | Dec 16, 2025 |
| Dec 15, 2025 | SOpen-market sale Common Stock | -8,147 | $69.96 | $570k | 3,971,255 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -8,416 | $60.51 | $509k | 3,962,839 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -10,963 | $61.25 | $671k | 3,951,876 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -14,095 | $62.12 | $876k | 3,937,781 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -8,476 | $62.94 | $533k | 3,929,305 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -6,661 | $64.29 | $428k | 3,922,644 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -1,000 | $64.96 | $65k | 3,921,644 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -1,300 | $65.77 | $86k | 3,920,344 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -166 | $66.77 | $11k | 3,920,178 | Dec 16, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -3,221 | $67.87 | $219k | 3,916,957 | Dec 16, 2025 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Patrick O'Brien COO | $3.1M 49,493 shares | -9% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $2.5M 40,164 shares | -19% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% | |
| 28Weak | ARROWHEAD PHARMACEUTICALS, INC. | Mauro Ferrari director | $527k 7,530 shares | -10% | |
| 35Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $677k 10,000 shares | -23% | |
| 45Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $1.8M 26,031 shares | -1% | |
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | William D. Waddill director | $566k 8,367 shares | -13% | |
| 36Weak | ARROWHEAD PHARMACEUTICALS, INC. | Victoria Vakiener director | $679k 10,040 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.